Daytrana ADHD treatment
May 28 2015 by
Ray Sahelian, M.D.

2006 ó The US Food and Drug Administration (FDA) has approved a once-daily methylphenidate transdermal system for the treatment of attention-deficit/hyperactivity disorder in children aged 6 to 12 years

Daytrana (methylphenidate transdermal system, Shire) is a prescription medication approved by the FDA for the treatment of attention deficit hyperactivity disorder (ADHD). Oral methylphenidate drugs should be considered prior to selecting Shire / Novenís Daytrana patch for treatment of attention deficit / hyperactivity disorder due to concerns about skin sensitization.

Daytrana dosage
Daytrana is a once daily transdermal patch formulation of methylphenidate. Daytrana is available in 10 mg, 15 mg, 20 mg and 30 mg dosage strengths. It is advisable to always start with a low dose, such as the 10 mg to see if there are side effects to Daytrana before taking higher amounts.

Side effects
Indian J Psychiatry. 2014 January. Methylphenidate and suicidal ideation: Report of two cases. Stimulant prescriptions are routinely used to treat Attention Deficit Hyperactivity Disorder. Reports of psychiatric symptoms that have occurred include euphoria, delirium, confusion, toxic psychosis, and hallucinations. Here, authors report two cases of Attention Deficit Hyperactivity Disorder who were prescribed methylphenidate. Both children developed suicidal ideation that abated after discontinuing the drug. There were no depressive symptoms reported along with it, and the ideation could not be explained on the basis of impulsivity either.

Daytrana Research
A randomized, double-blind, placebo-controlled, laboratory classroom assessment of methylphenidate transdermal system in children with ADHD.
Journal of Attention Disord. 2006. McGough JJ, Wigal SB, Abikoff H, Turnbow JM, Posner K. University of California, Los Angeles, Semel Institute for Neuroscience and Human Behavior, 90095,
This study evaluates the efficacy, duration of action, and tolerability of methylphenidate transdermal system Daytrana in children with ADHD. Participants were dose optimized over 5 weeks utilizing Daytrana patch doses of 10, 16, 20, and 27 mg applied in the morning and worn for 9 hours. Following optimization, 80 participants were randomized to 1 week of Daytrana or placebo followed by 1 week of the opposite treatment. Daytrana was well tolerated and displayed significant improvement compared with placebo. Treatment with Daytrana resulted in statistically significant improvements on all efficacy measures. Time course and therapeutic effects of Daytrana suggest that this novel methylphenidate delivery system is an efficacious once-daily treatment for ADHD.

Mol Neurobiol. 2015. Chronic Treatment with a Clinically Relevant Dose of Methylphenidate Increases Glutamate Levels in Cerebrospinal Fluid and Impairs Glutamatergic Homeostasis in Prefrontal Cortex of Juvenile Rats.